scholarly journals Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond

2020 ◽  
Vol 28 ◽  
pp. 204020662096171
Author(s):  
Dimitri Poddighe ◽  
Mohamad Aljofan
Keyword(s):  
Bacterial Infections ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Lactone Ring ◽  
Macrolide Antibiotics ◽  
Direct Benefit ◽  
Anti Inflammatory ◽  
Viral Respiratory Infections ◽  
Associated Species ◽  
Viral Respiratory

Macrolides are a large group of antibiotics characterised by the presence of a macro-lactone ring of variable size. The prototype of macrolide antibiotics, erythromycin was first produced by Streptomyces and associated species more than half a century ago; other related drugs were developed. These drugs have been shown to have several pharmacological properties: in addition to their antibiotic activity, they possess some anti-inflammatory properties and have been also considered against non-bacterial infections. In this review, we analysed the available clinical evidences regarding the potential anti-viral activity of macrolides, by focusing on erythromycin, clarithromycin and azithromycin. Overall, there is no significant evidences so far that macrolides might have a direct benefit on most of viral infections considered in this review (RSV, Influenza, coronaviruses, Ebola and Zika viruses). However, their clinical benefit cannot be ruled out without further and focused clinical studies. Macrolides may improve the clinical course of viral respiratory infections somehow, at least through indirect mechanisms relying on some and variable anti-inflammatory and/or immunomodulatory effects, in addition to their well-known antibacterial activity.

scholarly journals The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes

2021 ◽  
Author(s):  
Valentin Sencio ◽  
Marina Gomes Machado ◽  
François Trottein
Keyword(s):  
Gut Microbiota ◽  
Bacterial Infections ◽  
Respiratory Infections ◽  
Critical Role ◽  
Good Health ◽  
Disease Outcomes ◽  
And Function ◽  
Viral Respiratory Infections ◽  
The Impact ◽  
Viral Respiratory

AbstractBacteria that colonize the human gastrointestinal tract are essential for good health. The gut microbiota has a critical role in pulmonary immunity and host’s defense against viral respiratory infections. The gut microbiota’s composition and function can be profoundly affected in many disease settings, including acute infections, and these changes can aggravate the severity of the disease. Here, we discuss mechanisms by which the gut microbiota arms the lung to control viral respiratory infections. We summarize the impact of viral respiratory infections on the gut microbiota and discuss the potential mechanisms leading to alterations of gut microbiota’s composition and functions. We also discuss the effects of gut microbial imbalance on disease outcomes, including gastrointestinal disorders and secondary bacterial infections. Lastly, we discuss the potential role of the lung–gut axis in coronavirus disease 2019.

scholarly journals Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections

2021 ◽  
Author(s):  
Timo Huber ◽  
Philipp Steininger ◽  
Pascal Irrgang ◽  
Klaus Korn ◽  
Matthias Tenbusch ◽  
...  
Keyword(s):  
Legionella Pneumophila ◽  
False Positive ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Chlamydia Psittaci ◽  
Specific Flow ◽  
Antibody Assays ◽  
Positive Results ◽  
Viral Respiratory

AbstractSARS-CoV-2 antibody assays are used for epidemiological studies and for the assessment of vaccine responses in highly vulnerable patients. So far, data on cross-reactivity of SARS-CoV-2 antibody assays is limited. Here, we compared four enzyme-linked immunosorbent assays (ELISAs; Vircell SARS-CoV-2 IgM/IgA and IgG, Euroimmun SARS-CoV-2 IgA and IgG) for detection of anti-SARS-CoV-2 antibodies in 207 patients with COVID-19, 178 patients with serological evidence of different bacterial infections, 107 patients with confirmed viral respiratory disease, and 80 controls from the pre-COVID-19 era. In COVID-19 patients, the assays showed highest sensitivity in week 3 (Vircell-IgM/A and Euroimmun-IgA: 78.9% each) and after week 7 (Vircell-IgG: 97.9%; Euroimmun-IgG: 92.1%). The antibody indices were higher in patients with fatal disease. In general, IgM/IgA assays had only limited or no benefit over IgG assays. In patients with non-SARS-CoV-2 respiratory infections, IgG assays were more specific than IgM/IgA assays, and bacterial infections were associated with more false-positive results than viral infections. The specificities in bacterial and viral infections were 68.0 and 81.3% (Vircell-IgM/IgA), 84.8 and 96.3% (Euroimmun-IgA), 97.8 and 86.0% (Vircell-IgG), and 97.8 and 99.1% (Euroimmun-IgG), respectively. Sera from patients positive for antibodies against Mycoplasma pneumoniae, Chlamydia psittaci, and Legionella pneumophila yielded particularly high rates of unspecific false-positive results in the IgM/IgA assays, which was revealed by applying a highly specific flow-cytometric assay using HEK 293 T cells expressing the SARS-CoV-2 spike protein. Positive results obtained with anti-SARS-CoV-2 IgM/IgA ELISAs require careful interpretation, especially if there is evidence for prior bacterial respiratory infections.

scholarly journals Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections

2021 ◽  
Vol 12 ◽  
Author(s):  
Amos C. Lee ◽  
Yunjin Jeong ◽  
Sumin Lee ◽  
Haewook Jang ◽  
Allen Zheng ◽  
...  
Keyword(s):  
Interferon Beta ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Type I ◽  
Emerging Viruses ◽  
Respiratory Viral Infection ◽  
Respiratory Viral Infections ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 interferon (IFN-I) response occurs early during COVID-19 and other viral respiratory infections such as SARS and MERS. These observations prompt considering IFN-β as a prophylactic or early intervention for respiratory viral infections. A rationale for developing and testing intranasal interferon beta (IFN-β) as an immediately available intervention for new respiratory viral infections that will arise unexpectedly in the future is presented and supported by basic and clinical trial observations. IFN-β prophylaxis could limit the spread and consequences of an emerging respiratory viral infection in at-risk individuals while specific vaccines are being developed.

Bacteriophages: A Possible Choice for Treatment of Viral Respiratory Infections and COVID-19

2021 ◽  
Vol 17 ◽  
Author(s):  
Faezeh Abbaszadeh ◽  
Narges Eslami ◽  
Parisa Shiri Aghbash ◽  
Hamed Ebrahimzadeh Leylabadlo ◽  
Hossein Bannazadeh Baghi
Keyword(s):  
Viral Infections ◽  
Specific Activity ◽  
Respiratory Infections ◽  
Age Groups ◽  
Specific Antibodies ◽  
The World ◽  
Microbial Infections ◽  
Viral Respiratory Infections ◽  
Display Technique ◽  
Viral Respiratory

: Viral respiratory infections are a leading cause of illness and mortality in all age groups worldwide. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (COVID-19) has spread throughout the world, igniting the twenty-first century’s deadliest pandemic. Research has shown that phages, which are bacterial viruses, can help treat viral infections with the effect on the immune system and their antiviral activity. Phages have specific activity and affect only the target without any side effects on other parts of the human body. Human phage-related diseases have not been reported yet; therefore, phages can be a very safe treatment, especially in many viral infections. The results of clinical studies have a promising future regarding the use of phages. It is possible that the phages display technique aided in the production of SARS-CoV-2 specific antibodies against its viral protein, which prevented the virus from binding or replicating and preventing secondary microbial infections, which have been linked to many patient deaths. Furthermore, an effective antiviral vaccine can be produced by using the same technique. Given the growing number of coronaviruses cases around the world, in the present paper, we review the possible mechanisms of phages against the COVID-19 disease and the method that may be a solution to eliminate the virus.

Combined therapy for treatment of acute respiratory viral infections: analysis of combined complex AnviMax

2020 ◽  
pp. 33-48
Author(s):  
O. A. Gromova ◽  
I. Yu. Torshin
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Combined Therapy ◽  
Allergic Inflammation ◽  
Histamine Receptor ◽  
Receptor Blockers ◽  
Respiratory Viral Infections ◽  
Comprehensive Programs ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

The annual increase in the incidence of influenza, SARS, and the COVID‑19 pandemic indicate the need for comprehensive programs to support congenital antiviral immunity. To increase the effectiveness of the treatment of viral respiratory infections, it is important to attenuate the effects of the so-called cytokine storm and enhanced compensation of the patient’s comorbid pathologies. Increasing the availability of zinc, vitamin C and rutoside can improve the body’s resistance to viral infections. In addition to micronutrients, to reduce the activity of allergic inflammation, second-generation H1-histamine receptor blockers (loratadine, etc.) and calcium gluconate can be used. To lower the  temperature, it is important to include paracetamol in therapy.

scholarly journals Seasonality of Respiratory Viral Infections

2020 ◽  
Vol 7 (1) ◽  
pp. 83-101 ◽  
Author(s):  
Miyu Moriyama ◽  
Walter J. Hugentobler ◽  
Akiko Iwasaki
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Winter Season ◽  
Environmental Parameters ◽  
Effect Of Temperature ◽  
Contributing Factors ◽  
Temperature And Humidity ◽  
Respiratory Viral Infections ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza disease hit the human population like clockwork in the winter season in temperate regions. Moreover, epidemics caused by viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the newly emerging SARS-CoV-2 occur during the winter months. The mechanisms underlying the seasonal nature of respiratory viral infections have been examined and debated for many years. The two major contributing factors are the changes in environmental parameters and human behavior. Studies have revealed the effect of temperature and humidity on respiratory virus stability and transmission rates. More recent research highlights the importance of the environmental factors, especially temperature and humidity, in modulating host intrinsic, innate, and adaptive immune responses to viral infections in the respiratory tract. Here we review evidence of how outdoor and indoor climates are linked to the seasonality of viral respiratory infections. We further discuss determinants of host response in the seasonality of respiratory viruses by highlighting recent studies in the field.

scholarly journals Antivirals for Virus Induced Exacerbations of Asthma and COPD Treatment

2018 ◽  
Vol 24 (3) ◽  
pp. 152-156
Author(s):  
Grigorescu Cristina ◽  
Antoniu Sabina Antonela ◽  
Oţelea Marina Ruxandra ◽  
Ileana Antohe ◽  
Fildan Ariadna Petronela ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Bacterial Infections ◽  
Respiratory Infections ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Exacerbations ◽  
Starting Point ◽  
Viral Respiratory Infections ◽  
Potential Use ◽  
Viral Respiratory

Abstract Viral respiratory infections in patients with asthma or chronic obstructive pulmonary disease (COPD) can cause severe exacerbations, increasing the risk of secondary bacterial infections and having a significant impact on disease-related morbidity and mortality. Several antivirals such as oseltamivir and zanamivir evaluated in influenza and other virus-induced respiratory infections are discussed in this review as a starting point of their potential use in improving the outcome of asthma and COPD exacerbations. However, the efficacy of antiviral therapy for asthma/COPD exacerbations needs a further evaluation.

scholarly journals Nutritional status, diet and viral respiratory infections: perspectives for severe acute respiratory syndrome coronavirus 2

2020 ◽  
pp. 1-12 ◽  
Author(s):  
Ana Heloneida de Araújo Morais ◽  
Jailane de Souza Aquino ◽  
Juliana Kelly da Silva-Maia ◽  
Sancha Helena de Lima Vale ◽  
Bruna Leal Lima Maciel ◽  
...  
Keyword(s):  
Immune Response ◽  
Severe Acute Respiratory Syndrome ◽  
Nutritional Status ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Eating Habits ◽  
Low Grade ◽  
Viral Susceptibility ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

Abstract COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was recognised by the WHO as a pandemic in 2020. Host preparation to combat the virus is an important strategy to avoid COVID-19 severity. Thus, the relationship between eating habits, nutritional status and their effects on the immune response and further implications in viral respiratory infections is an important topic discussed in this review. Malnutrition causes the most diverse alterations in the immune system, suppressing of the immune response and increasing the susceptibility to infections such as SARS-CoV-2. On the other hand, obesity induces low-grade chronic inflammation caused by excess adiposity, which increases angiotensin-converting enzyme 2. It decreases the immune response favouring SARS-CoV-2 virulence and promoting respiratory distress syndrome. The present review highlights the importance of food choices considering their inflammatory effects, consequently increasing the viral susceptibility observed in malnutrition and obesity. Healthy eating habits, micronutrients, bioactive compounds and probiotics are strategies for COVID-19 prevention. Therefore, a diversified and balanced diet can contribute to the improvement of the immune response to viral infections such as COVID-19.

scholarly journals The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections

2020 ◽  
Vol 13 (9) ◽  
pp. 236 ◽  
Author(s):  
Alexander Panossian ◽  
Thomas Brendler
Keyword(s):  
Withania Somnifera ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Innate And Adaptive Immunity ◽  
Antiviral Effects ◽  
Viral Respiratory Infections ◽  
Resistance To Viral Infection ◽  
Viral Respiratory

The aim of our review is to demonstrate the potential of herbal preparations, specifically adaptogens for prevention and treatment of respiratory infections, as well as convalescence, specifically through supporting a challenged immune system, increasing resistance to viral infection, inhibiting severe inflammatory progression, and driving effective recovery. The evidence from pre-clinical and clinical studies with Andrographis paniculata, Eleutherococcus senticosus, Glycyrrhiza spp., Panax spp., Rhodiola rosea, Schisandra chinensis, Withania somnifera, their combination products and melatonin suggests that adaptogens can be useful in prophylaxis and treatment of viral infections at all stages of progression of inflammation as well as in aiding recovery of the organism by (i) modulating innate and adaptive immunity, (ii) anti-inflammatory activity, (iii) detoxification and repair of oxidative stress-induced damage in compromised cells, (iv) direct antiviral effects of inhibiting viral docking or replication, and (v) improving quality of life during convalescence.

Sign in / Sign up

Export Citation Format

Share Document